...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of hematologic oncology. >Rituximab in follicular lymphoma: the first chapter of the new era?
【24h】

Rituximab in follicular lymphoma: the first chapter of the new era?

机译：利妥昔单抗治疗滤泡性淋巴瘤：新时代的第一章？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Follicular lymphoma is the most common indolent B-cell lymphoma. Although there is no current standard of care adopted for all patients, clinical outcomes for patients with follicular lymphoma have significantly improved over the past few decades, which can be largely attributed to the incorporation of immunotherapy. Rituximab, a monoclonal antibody to the CD20 antigen, has been widely adopted in the treatment of B-cell lymphomas, resulting from improvements in remission duration and overall survival. We provide an evidence-based discussion of the clinical success and incorporation of immunotherapy, rituximab in the treatment of follicular lymphoma, the prototypical indolent B-cell lymphoma. This shift in the treatment paradigm has opened the door to novel, nonchemotherapy approaches in the treatment of patients with indolent B-cell lymphoma.
机译：滤泡性淋巴瘤是最常见的惰性B细胞淋巴瘤。尽管目前尚无适用于所有患者的护理标准，但在过去的几十年中，滤泡性淋巴瘤患者的临床结局已有显着改善，这在很大程度上可归因于免疫治疗的纳入。利妥昔单抗是一种针对CD20抗原的单克隆抗体，由于缓解时间和总体生存时间的改善，已被广泛用于B细胞淋巴瘤的治疗。我们提供了关于临床成功和免疫疗法，利妥昔单抗在滤泡性淋巴瘤，典型的惰性B细胞淋巴瘤治疗中的结合的循证讨论。治疗范例的这种转变为惰性B细胞淋巴瘤患者的治疗打开了新的，非化学疗法的大门。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号